輝瑞報價高未能成功納入內地醫保名單 另傳中方正就Paxlovid仿製藥洽談
國家醫保局公布,2022年國家醫保藥品目錄談判工作於昨日(8日)正式結束。今年共有阿茲夫定片、奈瑪特韋片/利托那韋片組合包裝(Paxlovid)、清肺排毒顆粒3種新冠治療藥品通過企業自主申報、形式審查、專家評審等程序,參與了談判。其中,阿茲夫定片、清肺排毒顆粒談判成功,Paxlovid因生產企業輝瑞(PFE.US)報價高未能成功。
國家醫保局醫藥管理司負責人表示,雖然Paxlovid未能通過談判納入醫保目錄,但根據近期國家醫保局會同有關部門聯合印發的《關於實施「乙類乙管」後優化新型冠狀病毒感染患者治療費用醫療保障相關政策的通知》要求,《新型冠狀病毒感染診療方案(試行第十版)》中的所有治療性藥物,包括Paxlovid、阿茲夫定片、莫諾拉韋膠囊、散寒化濕顆粒等,醫保都將臨時性支付到今年3月31日。在此期間,新冠病毒感染的參保患者使用該些藥品均可享受醫保報銷政策。
此外,阿茲夫定片、清肺排毒顆粒經過本次談判納入國家醫保藥品目錄後,國家醫保藥品目錄內治療發熱、咳嗽等新冠症狀的藥品已達600餘種。同時,為滿足各地新冠病毒感染患者治療的需要,近期各地醫保部門結合當地醫保基金運行情況,又將一批新冠對症治療藥物臨時納入本地區醫保支付範圍。
另據《每日經濟新聞》引述消息報道,部分中國企業早已擁有生產Paxlovid的能力,只是限於專利許可協議而不能直接向內地市場供應藥物。據悉,國家藥監局作為中方牽龍頭門正與輝瑞就Paxlovid的仿製藥合作進行談判,並特別提到華海藥業(600521.SH)及石藥集團(01093.HK)。惟相關企業暫未確認有關消息。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.